Lilly wins FDA nod for once-weekly insulin, Onswik (LLY:NYSE)
· seekingalpha.com
Eli Lilly (LLY) wins FDA approval for once-weekly insulin product, Onswik, for adults with type 2 diabetes, backed by Phase 3 QWINT data. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...